Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immuno-Biological Laboratories Co (TSE:4570) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Immuno-Biological Laboratories Co had a gross margin of 70.51% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Immuno-Biological Laboratories Co Gross Margin % Related Terms
Immuno-Biological Laboratories Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immuno-Biological Laboratories Co Gross Margin % Chart
TSE:4570 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Immuno-Biological Laboratories Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immuno-Biological Laboratories Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Immuno-Biological Laboratories Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Immuno-Biological Laboratories Co (TSE:4570) has a Gross Margin % of 70.51% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Immuno-Biological Laboratories Co and its competitors. This is 16% above median its historical median of 60.91. Over the past decade, Immuno-Biological Laboratories Co's Gross Margin % has ranged from 37.69 to 70.35. According to the industry distribution chart, Immuno-Biological Laboratories Co ranks #292 out of 732 companies in the Biotechnology industry, placing it in the top 39.9%.
Is Immuno-Biological Laboratories Co's Gross Margin % too high?
Immuno-Biological Laboratories Co's current Gross Margin % of 70.51% is 16% above median its 10-year median of 60.91. Over the past 10 years, this metric has ranged from a low of 37.69 to a high of 70.35. The Biotechnology industry median Gross Margin % is 60.91. Immuno-Biological Laboratories Co's value of 70.51% is 15.8% above this industry median. Based on the distribution chart, Immuno-Biological Laboratories Co ranks #292 out of 732 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immuno-Biological Laboratories Co has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immuno-Biological Laboratories Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Immuno-Biological Laboratories Co ranks #292 out of 732 companies for Gross Margin %. This puts Immuno-Biological Laboratories Co in the upper half of its industry. The industry median Gross Margin % is 60.91. Immuno-Biological Laboratories Co's value of 70.51% is 15.8% above this benchmark. Historically, Immuno-Biological Laboratories Co's own Gross Margin % has ranged from 37.69 to 70.35 over the past decade. While the company's 10-year median is 60.91 vs. the industry median of 60.91, Immuno-Biological Laboratories Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immuno-Biological Laboratories Co's current Gross Margin % of 70.51% is 15.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Immuno-Biological Laboratories Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immuno-Biological Laboratories Co's current Gross Margin % is 70.51%, which is 16% above median its own 10-year median of 60.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immuno-Biological Laboratories Co stock overvalued right now?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co (TSE:4570) is currently considered Significantly Overvalued. The stock's GF Value™ is 円578.92, compared to a current price of 円994.00 — trading 71.7% above its estimated fair value. The current Gross Margin % is 70.51%, which is 16% above median its 10-year median of 60.91 and 15.8% above the Biotechnology industry median of 60.91. Immuno-Biological Laboratories Co's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Immuno-Biological Laboratories Co (TSE:4570), the current Gross Margin % is 70.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immuno-Biological Laboratories Co (TSE:4570) Overvalued in 2026?
Based on GuruFocus' analysis, Immuno-Biological Laboratories Co stock appears to be overvalued.
The current stock price of 円994.00 is trading 71.7% above its estimated GF Value™ of 円578.92.
GuruFocus considers Immuno-Biological Laboratories Co to be Significantly Overvalued.
Key valuation signals for TSE:4570:
Gross Margin %: 70.51% (16% above median its 10-year median of 60.91)
GF Value™: 円578.92 vs. price of 円994.00 (71.7% above fair value)
Industry Position: 15.8% above the Biotechnology median (#292 of 732)
No single metric tells the full story. See the TSE:4570 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immuno-Biological Laboratories Co Business Description
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
61GF Score
Get the complete analysis for TSE:4570
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4570 has been successfully added to your 
